Competitor Analysis: Anti-Inflammatory Peptides
Delivery costs do not apply or are included.
Ask a question about this product
Competitor Analysis: Anti-Inflammatory Peptides
The present Competitive Intelligence Report about peptide therapeutics provides a competitor evaluation in the field of marketed and new molecules for treatment of inflammatory and autoimmune diseases as of September 2014. Anti-Inflammatory peptides under development and on the market are used for treatment of diseases ranging from psoriasis, multiple sclerosis, transplantation and autoimmune diseases. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently marketed and active projects in research and development of anti-inflammatory peptides. In addition, the report lists company-specific R&D pipelines of anti-inflammatory peptides. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Competitor Analysis: Anti-Inflammatory Peptides
Table of Contents
- 2013 Sales of Major Anti-Inflammatory Peptides
- Cardiovascular Diseases
- Dermatological Diseases
- Gastrointestinal Diseases
- Neurological Diseases
- Ophthalmological & Otorhino Diseases
- Pulmonary & Respiratory Diseases
- Renal Diseases
- Rheumatological & Autoimmune Diseases
- Transplantation
- Not-Specified Inflammatory & Autoimmune Diseases
- Corporate Anti-Inflammatory Peptide R&D Pipelines